Plain-English translation of NCT07935174 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new imaging scan called 68Ga-grazytracer PET that allows doctors to directly visualize immune cells and how hard they are working in your body. The scan tracks a specific molecule called granzyme B, which is released by immune cells when they fight cancer or autoimmune diseases. Researchers want to see if this scan can predict how well your treatment is working.
Current imaging methods cannot show doctors what immune cells are actually doing in your body during cancer or autoimmune disease treatment. This new scan could help doctors see immune activity directly and predict treatment success earlier, potentially changing how they manage your care.
You likely qualify if…
You likely don't qualify if…
You will receive a special imaging scan called PET/CT before you start your cancer or autoimmune disease treatment, and again during your treatment at scheduled times. The scan involves receiving a small injection of a radioactive tracer (68Ga-grazytracer), waiting a short time, and then lying still in a scanner for imaging. Your doctor will compare the scan results to how well your treatment is working and your disease activity over time.
AI-generated summary from trial data · Nov 15, 2026 · Not medical advice
China